bg content top home

Smarter science.
Better health.

NEW YORK / TEL AVIV — JUNE 4, 2018

RDD Pharma announced the appointment of Dr. Mark Sirgo as the Chairman of the Board of Directors. Dr. Sirgo’s experience with public company leadership from development stage to commercial enterprise brings additional value to the current Board’s expertise and experience.

RDD Pharma is a privately held specialty pharma company focused on fast-track development and commercialization of innovative therapeutics for anorectal diseases and lower-gastrointestinal tract disorders. The company has two clinical stage products and two pre-clinical products, all of which serve significant unmet needs. RDD-1219 for chronic anal fissure has completed enrollment in a European Phase 3. RDD-0315 for fecal incontinence, and indication for which there is no approved Rx product, has completed a Phase 2a study in Europe. The European Medicines Agency has granted RDD-0315 Orphan Drug status in spinal cord injury patients. An IND was filed in the US on May 30, 2018. Two pre-clinical assets are also in development for pruritus ani and radiation colitis/proctitis.

Target-icon

Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.

VISIT OUR TARGET PAGE

Strategey-icon

Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.

VISIT OUR STRATEGY PAGE

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

VISIT OUR PIPELINE PAGE

video

Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.

WATCH OUR VIDEO

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2018, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top